T his month's issue of JMCP contains 4 articles that deal with several complex matters related to the use of opiates. As is characteristic of recent publications on this topic, in either the professional or lay literature, the news is not particularly good. The articles included here illustrate many of the complexities and challenges in managing pain with this most ancient class of drugs. Kozma Kozma et al. provide a detailed pattern analysis of patient characteristics that include diagnoses, comorbidities, concomitant medications, and potential drug interactions in 85,000 commercially insured patients, with 4 categories of pain diagnoses receiving at least 1 prescription for an opiate. Many of the observations are compelling. Pain medications were prescribed by a mean of 4.5 prescribers over the 2-year observation period. Nearly half the patients were prescribed adjuvant drug therapy for pain. Comorbid conditions were commonly present and treated with medications. Approximately one-third of the patients were exposed to a potential drug interaction, and as the authors note, medication use is likely underreported because of the supposition that these patients also use overthe-counter medications not captured by the claims database.
Pergolizzi et al. further elaborate on the consequences of concomitant drug therapy with long-acting opiates (LAO) by capturing the differential health care costs in a population of commercially insured patients exposed to potential major drug-drug interactions. Of the more than 57,000 patients included in the study, 5.7% were prescribed drugs with poten-
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tial for a significant drug interaction with LAOs, resulting in additional total health care costs of $609 per month during the 3-month observation period.
These 2 articles identify a subset of the difficulties clinicians must address when prescribing opiate medications for the treatment of pain. In the complicated process of providing care to pain patients, pharmacists in managed care have the opportunity to provide valuable care coordination support. The multiplicity of prescribers and potentially interacting medications are substrates for claims editing, educational outreach, and product selection activities that are core services provided by managed care pharmacists.
The 2 reports on controlled substances in the Medicaid program bespeak another significant public health problem with the opiate class of drugs: the diversion, misuse, and abuse of opiates. The Massachusetts Medicaid program has made incremental changes over the past decade that are intended to promote optimal use of opiates and has achieved some measure of success as described in the article by Garcia et al. Many of the steps taken by Massachusetts were intended, among other things, to decrease the volume of opiates in the local marketplace. Yet, the epidemic of opiate abuse and overdose deaths marches on, compelling Governor Deval Patrick to declare a public health emergency in Massachusetts on March 27, 2014, and issue certain executive orders. 1 The commentary by Roberts and Skinner identifies a frequently utilized, but largely unproven, strategy employed by Medicaid programs to address apparent opiate misuse-the so-called Medicaid lock-in program (MLIP). Roberts and Skinner expose the variability among the programs, the dearth of literature documenting the impact of the programs, and the apparent unfulfilled potential for these programs to promote coordinated care among enrollees.
The bibliography of literature concerning the trials and tribulations of managing pain with opiates and the parallel problems with opiate misuse is encyclopedic. A call to action resounds. Over the past decade or so, we have seen the emergence of pain as the fifth vital sign. Health care providers throughout the spectrum of care are trained to assess patients' level of pain and are then challenged to choose an appropriate treatment for a highly subjective condition. This scenario has created this dilemma: In an attempt to prevent the undertreatment of pain, we have invited therapeutic misadventures, including the overprescribing of opiate pain relievers.
The increase in opiate prescriptions and the corresponding escalation of prescription opioid abuse are well documented. The opportunity for managed care pharmacy to have a significant impact in promoting evidence-based pharmacotherapy for pain along with effective management strategies to minimize the risk of utilizing opiates is apparent. Pharmacists must work in collaboration with other members of the care delivery system but are uniquely positioned to offer valuable professional services.
Several predictive modelling approaches can help identify those at increased risk of misusing opiates.
2,3 Managed pharmacy should implement algorithms to identify those at risk, limit exposure to nonmedical use of opiates, and devise approaches to promote optimal care. At-risk patients, identified through pharmacy claims coupled with medical diagnosis and claims data, should be referred to case or care management programs to assist referrals to the appropriate providers. Information technology solutions, such as prescription monitoring programs (PMPs) 4 and electronic prescribing, must be further developed and integrated into the prescribing process so the data can be readily viewed by clinicians and the promise of PMPs and e-prescribing can be fully realized.
The literature abounds with guidelines, recommendations, commentaries, and research on the topic of opiate treatment of pain. It is incumbent upon the health care system to respond to the call to thwart the escalating public health threat attributable to the diversion and overdose of opiates. Managed care pharmacists have the tools and the imperative to make a significant contribution to improving the care of pain patients and protecting against the misuse and abuse of opiates.
